{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T17:51:30Z","timestamp":1792086690011,"version":"4.4.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T00:00:00Z","timestamp":1791936000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:00:00Z","timestamp":1792022400000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Rheumatol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Depressive symptoms are common in psoriatic arthritis (PsA) and may influence treatment response. This study examined their association with achieving remission after starting a new systemic antirheumatic therapy, and tested whether this association differs by sex.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Data from PsA patients in the ongoing prospective longitudinal observational cohort study RABBIT-SpA were analyzed. Depressive symptoms were assessed with the WHO-5 Well-Being Index (none\/mild vs. moderate\/severe). Outcomes included minimal disease activity (MDA) and Disease Activity in Psoriatic Arthritis (DAPSA) remission at 3 and 6 months. Logistic regression assessed the association between baseline well-being and remission, adjusted for confounders identified using directed acyclic graphs. A sex \u00d7 well-being interaction term was included in each model to test whether this association differs by sex. Multiple imputation handled missing data.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Moderate\/severe depressive symptoms were present in 29% of 1,888 patients (34% of women, 23% of men). In adjusted analyses, higher baseline well-being was associated with remission (OR per 10-point increase: 1.06\u20131.14 across outcomes and timepoints, reaching significance for MDA at 6 months and DAPSA remission at both timepoints). Interaction testing showed no evidence that this association differed by sex; all four 95% confidence intervals included 1 (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009\u2265\u20090.29). Both sexes with moderate\/severe symptoms achieved MDA and DAPSA remission less frequently than those with no\/mild symptoms. Although disease activity improved in both groups over time, it remained higher in patients with moderate\/severe symptoms.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Depressive symptoms were associated with higher disease activity and less frequent remission in PsA, with no evidence that this effect differed by sex. Routine screening for depressive symptoms should be considered in PsA management to identify patients at risk of suboptimal treatment response.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical trial number<\/jats:title>\n                    <jats:p>Not applicable.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s41927-026-00707-y","type":"journal-article","created":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T05:36:52Z","timestamp":1792042612000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Depressive symptoms are associated with achieving remission in PsA patients \u2013 an analysis from the RABBIT-SpA register"],"prefix":"10.1186","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3729-0772","authenticated-orcid":false,"given":"Andreas","family":"Reich","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2069-2190","authenticated-orcid":false,"given":"Anja","family":"Wei\u00df","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8416-0463","authenticated-orcid":false,"given":"Lisa","family":"Lindner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8028-8099","authenticated-orcid":false,"given":"Martin","family":"Feuchtenberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-0493-510X","authenticated-orcid":false,"given":"Georg","family":"Dahmen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8197-8681","authenticated-orcid":false,"given":"Hanns-Martin","family":"Lorenz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9475-9362","authenticated-orcid":false,"given":"Xenofon","family":"Baraliakos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2456-4049","authenticated-orcid":false,"given":"Anne C.","family":"Regierer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,14]]},"reference":[{"issue":"1","key":"707_CR1","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/s41572-021-00293-y","volume":"7","author":"O FitzGerald","year":"2021","unstructured":"FitzGerald O, Ogdie A, Chandran V, Coates LC, Kavanaugh A, Tillett W, et al. Psoriatic arthritis. Nat Reviews Disease Primers. 2021;7(1):59.","journal-title":"Nat Reviews Disease Primers"},{"issue":"2","key":"707_CR2","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/s00296-020-04775-2","volume":"41","author":"S Gupta","year":"2021","unstructured":"Gupta S, Syrimi Z, Hughes DM, Zhao SS. Comorbidities in psoriatic arthritis: a systematic review and meta-analysis. Rheumatol Int. 2021;41(2):275\u201384.","journal-title":"Rheumatol Int"},{"issue":"1","key":"707_CR3","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/s10067-019-04734-8","volume":"39","author":"SS Zhao","year":"2020","unstructured":"Zhao SS, Miller N, Harrison N, Duffield SJ, Dey M, Goodson NJ. Systematic review of mental health comorbidities in psoriatic arthritis. Clin Rheumatol. 2020;39(1):217\u201325.","journal-title":"Clin Rheumatol"},{"issue":"1","key":"707_CR4","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1186\/s13075-023-03127-2","volume":"25","author":"A Reich","year":"2023","unstructured":"Reich A, Wei\u00df A, Lindner L, Baraliakos X, Poddubnyy D, Zinke S, et al. Depressive symptoms are associated with fatigue, poorer functional status and less engagement in sports in axSpA and PsA: an analysis from the RABBIT-SpA cohort. Arthritis Res Ther. 2023;25(1):136.","journal-title":"Arthritis Res Ther"},{"issue":"11","key":"707_CR5","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.1136\/annrheumdis-2017-211284","volume":"76","author":"B Michelsen","year":"2017","unstructured":"Michelsen B, Kristianslund EK, Sexton J, Hammer HB, Fagerli KM, Lie E, et al. Do depression and anxiety reduce the likelihood of remission in rheumatoid arthritis and psoriatic arthritis? Data from the prospective multicentre NOR-DMARD study. Ann Rheum Dis. 2017;76(11):1906\u201310.","journal-title":"Ann Rheum Dis"},{"key":"707_CR6","doi-asserted-by":"crossref","unstructured":"Snoeck Henkemans SVJ, Vis M, Koc GH, Luime JJ, Kok MR, Tchetverikov I, et al. Association between depression and anxiety and inability to achieve remission in rheumatoid arthritis and psoriatic arthritis. Rheumatology (Oxford). 2025;64(5):2411\u201321.","DOI":"10.1093\/rheumatology\/keae621"},{"issue":"9","key":"707_CR7","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1002\/acr.24593","volume":"74","author":"A Wong","year":"2022","unstructured":"Wong A, Ye JY, Cook RJ, Gladman DD, Chandran V. Depression and Anxiety Reduce the Probability of Achieving a State of Sustained Minimal Disease Activity in Patients With Psoriatic Arthritis. Arthritis Care Res (Hoboken). 2022;74(9):1430\u20134.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"707_CR8","doi-asserted-by":"crossref","unstructured":"Reich A, Wei\u00df A, Lindner L, Zinke S, Stille C, Detert J, et al. Effect of depressive symptoms on treatment response in patients with axSpA: data from the RABBIT-SpA register. RMD Open. 2025;11(2):e005422.","DOI":"10.1136\/rmdopen-2025-005422"},{"issue":"12","key":"707_CR9","doi-asserted-by":"publisher","first-page":"5734","DOI":"10.1093\/rheumatology\/keab242","volume":"60","author":"SS Zhao","year":"2021","unstructured":"Zhao SS, Jones GT, Hughes DM, Moots RJ, Goodson NJ. Depression and anxiety symptoms at TNF inhibitor initiation are associated with impaired treatment response in axial spondyloarthritis. Rheumatology (Oxford). 2021;60(12):5734\u201342.","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"707_CR10","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1007\/s10067-023-06806-2","volume":"43","author":"A Martins","year":"2024","unstructured":"Martins A, Oliveira D, Nicolau R, Rocha TM, Bernardo A, Costa L, et al. What is the association of depression with clinical response to therapy in patients with psoriatic arthritis treated with biologic disease-modifying antirheumatic drugs? Clin Rheumatol. 2024;43(1):251\u20138.","journal-title":"Clin Rheumatol"},{"issue":"1","key":"707_CR11","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1186\/s13075-025-03650-4","volume":"27","author":"L Lindner","year":"2025","unstructured":"Lindner L, Wei\u00df A, Reich A, Baumann C, Behrens F, Baraliakos X, et al. Real-world sex differences in treatment persistence and reasons for discontinuation in psoriatic arthritis patients: results from the German RABBIT-SpA register. Arthritis Res Ther. 2025;27(1):188.","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"707_CR12","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1186\/s13075-021-02563-2","volume":"23","author":"L Lindner","year":"2021","unstructured":"Lindner L, Wei\u00df A, Reich A, Kindler S, Behrens F, Braun J, et al. Implementing an automated monitoring process in a digital, longitudinal observational cohort study. Arthritis Res Ther. 2021;23(1):181.","journal-title":"Arthritis Res Ther"},{"issue":"2","key":"707_CR13","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s00393-019-0613-z","volume":"79","author":"AC Regierer","year":"2020","unstructured":"Regierer AC, Wei\u00df A, Baraliakos X, Zink A, Listing J, Strangfeld A. [RABBIT-SpA: a new disease register for axial spondyloarthritis and psoriatic arthritis]. Z Rheumatol. 2020;79(2):135\u201342.","journal-title":"Z Rheumatol"},{"key":"707_CR14","unstructured":"UNESCO Institute for Statistics. International standard classification of education: ISCED 2011. Montreal: UNESCO Institute for Statistics; 2012."},{"issue":"8","key":"707_CR15","doi-asserted-by":"publisher","first-page":"2665","DOI":"10.1002\/art.21972","volume":"54","author":"W Taylor","year":"2006","unstructured":"Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum. 2006;54(8):2665\u201373.","journal-title":"Arthritis Rheum"},{"issue":"6","key":"707_CR16","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1136\/ard.2007.084244","volume":"68","author":"WP Maksymowych","year":"2009","unstructured":"Maksymowych WP, Mallon C, Morrow S, Shojania K, Olszynski WP, Wong RL, et al. Development and validation of the Spondyloarthritis Research Consortium of Canada (SPARCC) Enthesitis Index. Ann Rheum Dis. 2009;68(6):948\u201353.","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"707_CR17","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.3899\/jrheum.171183","volume":"45","author":"A Cauli","year":"2018","unstructured":"Cauli A, Gladman DD, Mathieu A, Olivieri I, Porru G, Tak PP, et al. Physician\u2019s Global Assessment in Psoriatic Arthritis: A Multicenter GRAPPA Study. J Rheumatol. 2018;45(9):1256\u201362.","journal-title":"J Rheumatol"},{"issue":"5","key":"707_CR18","doi-asserted-by":"publisher","first-page":"898","DOI":"10.3899\/jrheum.100857","volume":"38","author":"A Cauli","year":"2011","unstructured":"Cauli A, Gladman DD, Mathieu A, Olivieri I, Porru G, Tak PP, et al. Patient global assessment in psoriatic arthritis: a multicenter GRAPPA and OMERACT study. J Rheumatol. 2011;38(5):898\u2013903.","journal-title":"J Rheumatol"},{"issue":"6","key":"707_CR19","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1136\/annrheumdis-2014-205207","volume":"73","author":"L Gossec","year":"2014","unstructured":"Gossec L, de Wit M, Kiltz U, Braun J, Kalyoncu U, Scrivo R, et al. A patient-derived and patient-reported outcome measure for assessing psoriatic arthritis: elaboration and preliminary validation of the Psoriatic Arthritis Impact of Disease (PsAID) questionnaire, a 13-country EULAR initiative. Ann Rheum Dis. 2014;73(6):1012\u20139.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"707_CR20","first-page":"439","volume":"13","author":"JA Husted","year":"1995","unstructured":"Husted JA, Gladman DD, Long JA, Farewell VT. A modified version of the Health Assessment Questionnaire (HAQ) for psoriatic arthritis. Clin Exp Rheumatol. 1995;13(4):439\u201343.","journal-title":"Clin Exp Rheumatol"},{"issue":"3","key":"707_CR21","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","volume":"19","author":"AY Finlay","year":"1994","unstructured":"Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI) - a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19(3):210\u20136.","journal-title":"Clin Exp Dermatol"},{"issue":"8","key":"707_CR22","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1136\/ard.2009.122259","volume":"69","author":"M Schoels","year":"2010","unstructured":"Schoels M, Aletaha D, Funovits J, Kavanaugh A, Baker D, Smolen JS. Application of the DAREA\/DAPSA score for assessment of disease activity in psoriatic arthritis. Ann Rheum Dis. 2010;69(8):1441\u20137.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"707_CR23","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1136\/ard.2008.102053","volume":"69","author":"LC Coates","year":"2010","unstructured":"Coates LC, Fransen J, Helliwell PS. Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment. Ann Rheum Dis. 2010;69(1):48\u201353.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"707_CR24","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1159\/000376585","volume":"84","author":"CW Topp","year":"2015","unstructured":"Topp CW, \u00d8stergaard SD, S\u00f8ndergaard S, Bech P. The WHO-5 Well-Being Index: A Systematic Review of the Literature. Psychother Psychosom. 2015;84(3):167\u201376.","journal-title":"Psychother Psychosom"},{"key":"707_CR25","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.diabres.2017.07.005","volume":"132","author":"JA Halliday","year":"2017","unstructured":"Halliday JA, Hendrieckx C, Busija L, Browne JL, Nefs G, Pouwer F, et al. Validation of the WHO-5 as a first-step screening instrument for depression in adults with diabetes: Results from Diabetes MILES \u2013 Australia. Diabetes Res Clin Pract. 2017;132:27\u201335.","journal-title":"Diabetes Res Clin Pract"},{"issue":"2","key":"707_CR26","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/S0165-0327(02)00237-9","volume":"78","author":"B L\u00f6we","year":"2004","unstructured":"L\u00f6we B, Spitzer RL, Gr\u00e4fe K, Kroenke K, Quenter A, Zipfel S, et al. Comparative validity of three screening questionnaires for DSM-IV depressive disorders and physicians\u2019 diagnoses. J Affect Disord. 2004;78(2):131\u201340.","journal-title":"J Affect Disord"},{"issue":"7","key":"707_CR27","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1136\/annrheumdis-2017-212629","volume":"77","author":"I Redeker","year":"2018","unstructured":"Redeker I, Hoffmann F, Callhoff J, Haibel H, Sieper J, Zink A, et al. Determinants of psychological well-being in axial spondyloarthritis: an analysis based on linked claims and patient-reported survey data. Ann Rheum Dis. 2018;77(7):1017\u201324.","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"707_CR28","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1136\/annrheumdis-2015-207507","volume":"75","author":"MM Schoels","year":"2016","unstructured":"Schoels MM, Aletaha D, Alasti F, Smolen JS. Disease activity in psoriatic arthritis (PsA): defining remission and treatment success using the DAPSA score. Ann Rheum Dis. 2016;75(5):811\u20138.","journal-title":"Ann Rheum Dis"},{"key":"707_CR29","doi-asserted-by":"publisher","DOI":"10.1201\/9780429492259","volume-title":"Flexible Imputation of Missing Data","author":"S van Buuren","year":"2018","unstructured":"van Buuren S. Flexible Imputation of Missing Data. 2nd ed. Boca Raton, FL: Chapman & Hall\/CRC; 2018.","edition":"2"},{"issue":"4","key":"707_CR30","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1002\/sim.4067","volume":"30","author":"IR White","year":"2011","unstructured":"White IR, Royston P, Wood AM. Multiple imputation using chained equations: Issues and guidance for practice. Stat Med. 2011;30(4):377\u201399.","journal-title":"Stat Med"},{"issue":"3","key":"707_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v045.i03","volume":"45","author":"S van Buuren","year":"2011","unstructured":"van Buuren S, Groothuis-Oudshoorn K. mice: Multivariate Imputation by Chained Equations in R. J Stat Softw. 2011;45(3):1\u201367.","journal-title":"J Stat Softw"},{"issue":"10","key":"707_CR32","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.3899\/jrheum.160904","volume":"44","author":"AM Orbai","year":"2017","unstructured":"Orbai AM, de Wit M, Mease PJ, Callis Duffin K, Elmamoun M, Tillett W, et al. Updating the Psoriatic Arthritis (PsA) Core Domain Set: A Report from the PsA Workshop at OMERACT 2016. J Rheumatol. 2017;44(10):1522\u20138.","journal-title":"J Rheumatol"},{"issue":"3","key":"707_CR33","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1177\/0962280206074463","volume":"16","author":"S van Buuren","year":"2007","unstructured":"van Buuren S. Multiple imputation of discrete and continuous data by fully conditional specification. Stat Methods Med Res. 2007;16(3):219\u201342.","journal-title":"Stat Methods Med Res"},{"key":"707_CR34","doi-asserted-by":"crossref","unstructured":"Rubin DB. Multiple imputation for nonresponse in surveys. New York: John Wiley & Sons, Inc.; 1987.","DOI":"10.1002\/9780470316696"},{"key":"707_CR35","volume-title":"R: A Language and Environment for Statistical Computing","author":"RC Team","year":"2024","unstructured":"Team RC. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing; 2024."},{"issue":"4","key":"707_CR36","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/j.rdc.2009.10.001","volume":"35","author":"J Fransen","year":"2009","unstructured":"Fransen J, van Riel PLCM. The Disease Activity Score and the EULAR Response Criteria. Rheumatic Disease Clin. 2009;35(4):745\u201357.","journal-title":"Rheumatic Disease Clin"},{"issue":"1","key":"707_CR37","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1136\/ard.2010.138594","volume":"70","author":"P Machado","year":"2011","unstructured":"Machado P, Landew\u00e9 R, Lie E, Kvien TK, Braun J, Baker D, et al. Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores. Ann Rheum Dis. 2011;70(1):47\u201353.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"707_CR38","doi-asserted-by":"publisher","first-page":"488","DOI":"10.3899\/jrheum.220386","volume":"50","author":"LC Coates","year":"2023","unstructured":"Coates LC, van der Horst-Bruinsma IE, Lubrano E, Beaver S, Drane E, Ufuktepe B, et al. Sex-Specific Differences in Patients With Psoriatic Arthritis: A Systematic Review. J Rheumatol. 2023;50(4):488\u201396.","journal-title":"J Rheumatol"},{"issue":"12","key":"707_CR39","doi-asserted-by":"publisher","first-page":"e716","DOI":"10.1016\/S2665-9913(23)00264-3","volume":"5","author":"L Eder","year":"2023","unstructured":"Eder L, Mylvaganam S, Pardo Pardo J, Petkovic J, Strand V, Mease P, et al. Sex-related differences in patient characteristics, and efficacy and safety of advanced therapies in randomised clinical trials in psoriatic arthritis: a systematic literature review and meta-analysis. Lancet Rheumatol. 2023;5(12):e716\u201327.","journal-title":"Lancet Rheumatol"},{"issue":"1","key":"707_CR40","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/s41746-025-01879-6","volume":"8","author":"K Sippli","year":"2025","unstructured":"Sippli K, Deckert S, Schmitt J, Scheibe M. Healthcare effects and evidence robustness of reimbursable digital health applications in Germany: a systematic review. NPJ Digit Med. 2025;8(1):495.","journal-title":"NPJ Digit Med"},{"issue":"1","key":"707_CR41","doi-asserted-by":"publisher","first-page":"e0228100","DOI":"10.1371\/journal.pone.0228100","volume":"15","author":"C Twomey","year":"2020","unstructured":"Twomey C, O\u2019Reilly G, B\u00fcltmann O, Meyer B. Effectiveness of a tailored, integrative Internet intervention (deprexis) for depression: Updated meta-analysis. PLoS ONE. 2020;15(1):e0228100.","journal-title":"PLoS ONE"},{"key":"707_CR42","doi-asserted-by":"publisher","first-page":"e42976","DOI":"10.2196\/42976","volume":"26","author":"A Etzelmueller","year":"2024","unstructured":"Etzelmueller A, Heber E, Horvath H, Radkovsky A, Lehr D, Ebert DD. The Evaluation of the GET.ON Nationwide Web-Only Treatment Service for Depression- and Stress-Related Symptoms: Naturalistic Trial. J Med Internet Res. 2024;26:e42976.","journal-title":"J Med Internet Res"},{"issue":"2\u20133","key":"707_CR43","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/S0304-3959(00)00379-1","volume":"89","author":"L Sharpe","year":"2001","unstructured":"Sharpe L, Sensky T, Timberlake N, Ryan B, Brewin CR, Allard S. A blind, randomized, controlled trial of cognitive-behavioural intervention for patients with recent onset rheumatoid arthritis: preventing psychological and physical morbidity. Pain. 2001;89(2\u20133):275\u201383.","journal-title":"Pain"},{"issue":"3","key":"707_CR44","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1037\/0022-006X.76.3.408","volume":"76","author":"AJ Zautra","year":"2008","unstructured":"Zautra AJ, Davis MC, Reich JW, Nicassario P, Tennen H, Finan P, et al. Comparison of cognitive behavioral and mindfulness meditation interventions on adaptation to rheumatoid arthritis for patients with and without history of recurrent depression. J Consult Clin Psychol. 2008;76(3):408\u201321.","journal-title":"J Consult Clin Psychol"}],"container-title":["BMC Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41927-026-00707-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41927-026-00707-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41927-026-00707-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T17:34:35Z","timestamp":1792085675000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41927-026-00707-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,14]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["707"],"URL":"https:\/\/doi.org\/10.1186\/s41927-026-00707-y","relation":{},"ISSN":["2520-1026"],"issn-type":[{"value":"2520-1026","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,14]]},"assertion":[{"value":"30 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study is conducted in accordance with the Declaration of Helsinki and was approved by the Ethics committee of the Charit\u00e9 - Universit\u00e4tsmedizin Berlin (EA1\/246\/16). Participants gave written informed consent to participate in the study before taking part.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"<b>Declarations<\/b>"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"<b>Declarations<\/b>"}},{"value":"AR: The author declares no competing interests.AW: The author declares no competing interests.LL: The author declares no competing interests.GD: The author declares no competing interests.MF: Reports grants\/research support from AbbVie, Novartis, Pfizer, and Roche; and honoraria or fees for speaking, consultancy, or advisory board membership from AbbVie, Boehringer Ingelheim, Eli Lilly, Galapagos, Janssen-Cilag, Novartis, Pfizer, Roche, and UCB.HML: Reports grants, conference support, honoraria for talks or advisory activities, or support for scientific meetings from AbbVie, Actelion, Alexion, Amgen, AstraZeneca, Baxter, Bayer Vital, Biocon, Biogen, Boehringer Ingelheim, BMS, Celgene, Celltrion, Chugai, Fresenius, Galapagos, Genzyme, Gilead, GSK, Hexal, Janssen-Cilag, Lilly, Medac, MSD, Mundipharma, Mylan, Nordic, Novartis, Octapharma, Pfizer, Roche, Sandoz, Sanofi, Shire, SOBI, Stada, Takeda, Thermo Fisher, UCB, and Vifor.XB: Reports consultancy or scientific advisory board fees from AbbVie, Advanz, Alexion, Alphasigma, Amgen, AstraZeneca, BMS, Cesas, Celltrion, Clarivate, Galapagos, J&J, Lilly, Moonlake, Novartis, Peervoice, Pfizer, Roche, Sandoz, Springer, Stada, Takeda, UCB, and Zuellig; research grants from AbbVie, Celltrion, Janssen, Moonlake, and Novartis; ASAS Past President and EULAR President-Elect.ACR: Reports speaker fees from Amgen, BMS, and Novartis.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"<b>Declarations<\/b>"}}],"article-number":"79"}}